Is exercise effective in reducing the risk of breast cancer in postmenopausal women?

Por Pritchard, Kathleen I.
Publicado em 2004

BCG in the treatment of cancer

Por Pritchard, Kathleen I.
Publicado em 1983

Who should participate in clinical trials and who not? Can clinical trials be made more efficient and effective?

Por Pritchard, Kathleen I
Publicado em 2008

Tailored targeted therapy for all: a realistic and worthwhile objective against

Por Pritchard, Kathleen I
Publicado em 2009

Do selective serotonin receptor inhibitor antidepressants reduce tamoxifen's effectiveness and increase the risk of death from breast cancer?

Por Pritchard, Kathleen I
Publicado em 2010

Overdiagnosing Overdiagnosis

Por Yaffe, Martin J., Pritchard, Kathleen I.
Publicado em 2014

Raloxifene: handle with care

Por Pritchard, Kathleen I., Levine, Mark, Walley, Barbara
Publicado em 2001

Clinical practice guidelines for the care and treatment of breast cancer: 14. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer

Por Pritchard, Kathleen I., Khan, Humaira, Levine, Mark
Publicado em 2002

Cost-Effectiveness Analysis of Recurrence Score-Guided Treatment Using a 21-Gene Assay in Early Breast Cancer

Por Tsoi, Daphne T., Inoue, Miho, Kelly, Catherine M., Verma, Sunil, Pritchard, Kathleen I.
Publicado em 2010

Review of the Clinical Studies Using the 21-Gene Assay

Por Kelly, Catherine M., Warner, Ellen, Tsoi, Daphne T., Verma, Sunil, Pritchard, Kathleen I.
Publicado em 2010

Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines

Por Eng, Lawson, Ibrahim-zada, Irada, Jarjanazi, Hamdi, Savas, Sevtap, Meschian, Mehran, Pritchard, Kathleen I, Ozcelik, Hilmi
Publicado em 2011

Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2– Advanced Breast Cancer

Por Pritchard, Kathleen I., Chia, Stephen K., Simmons, Christine, McLeod, Deanna, Paterson, Alexander, Provencher, Louise, Rayson, Daniel
Publicado no Oncologist (2016)

Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study

Por Kelly, Catherine M, Juurlink, David N, Gomes, Tara, Duong-Hua, Minh, Pritchard, Kathleen I, Austin, Peter C, Paszat, Lawrence F
Publicado em 2010

A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials

Por Spears, Melanie, Yousif, Fouad, Lyttle, Nicola, Boutros, Paul C., Munro, Alison F., Twelves, Chris, Pritchard, Kathleen I., Levine, Mark N., Shepherd, Lois, Bartlett, John MS.
Publicado no Oncotarget (2015)

A Phase II Study of Pazopanib in Patients with Recurrent or Metastatic Invasive Breast Carcinoma: A Trial of the Princess Margaret Hospital Phase II Consortium

Por Taylor, Sara K., Chia, Stephen, Dent, Susan, Clemons, Mark, Agulnik, Mark, Grenci, Pamela, Wang, Lisa, Oza, Amit M., Ivy, Percy, Pritchard, Kathleen I., Leighl, Natasha B.
Publicado em 2010

Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29

Por Chapman, Judith-Anne W., Costantino, Joseph P., Dong, Bin, Margolese, Richard G., Pritchard, Kathleen I., Shepherd, Lois E., Gelmon, Karen A., Wolmark, Norman, Pollak, Michael N.
Publicado no Breast Cancer Res Treat (2015)

Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27

Por Chapman, Judith-Anne W., Shepherd, Lois E., Ingle, James N., Muss, Hyman B., Pritchard, Kathleen I., Gelmon, Karen A., Whelan, Timothy J., Elliott, Catherine, Goss, Paul E.
Publicado no Breast Cancer Res Treat (2016)

Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study

Por Sgroi, Dennis C., Chapman, Judy-Anne W., Badovinac-Crnjevic, T., Zarella, Elizabeth, Binns, Shemeica, Zhang, Yi, Schnabel, Catherine A., Erlander, Mark G., Pritchard, Kathleen I., Han, Lei, Shepherd, Lois E., Goss, Paul E., Pollak, Michael
Publicado no Breast Cancer Res (2016)

Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA.12 Trial and BC Cohort

Por Chapman, Judith-Anne W, Nielsen, Torsten O, Ellis, Matthew J, Bernard, Phillip, Chia, Stephen, Gelmon, Karen A, Pritchard, Kathleen I, Maitre, Aurelie Le, Goss, Paul E, Leung, Samuel, Shepherd, Lois E, Bramwell, Vivien H C
Publicado em 2013

A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22

Por Trudeau, Maureen Elizabeth, Chapman, Judith-Anne W., Guo, Baoqing, Clemons, Mark J., Dent, Rebecca A., Jong, Roberta A., Kahn, Harriette J., Pritchard, Kathleen I., Han, Lei, O’Brien, Patti, Shepherd, Lois E., Parissenti, Amadeo M.
Publicado no Springerplus (2015)